News

CSR Pharma Group (ChemSun Research) cooperates with Rutgers University to initiate New Jersey Economic Development Authority (NJEDA) CSIT-funded Pilot Study of a Novel Biological Platform for Genome-Associated Precision Therapies (GAPTX) in GBM Brain Cancers using an in vivo Mouse Orthotopic Xenograft GBM Cancer Model.

September 2023

CSR Pharma Group (ChemSun Research) receives approval from National Science Foundation for the submission of a full grant application to the Federal SBIR/STTR Program.

June 2023

CSR Pharma Group Inc is a Recipient of the highly competitive New Jersey Economic Development Authority (NJEDA) Manufacturing Grants for Biological Drug Manufacturing.

May 2023

CSR Pharma Group (ChemSun Research) progresses towards acquiring second Discovery Technology and partnering with Scientific Founders at Research Institution to continue with additional Pivotal Preclinical Research Studies and IND Enabling Study program.

December 2022

CSR Pharma Group Inc is a Recipient of the highly competitive New Jersey Economic Development Authority (NJEDA) CSIT Catalyst R&D Grants for Innovation, Science & Technology.

The New Jersey Commission on Science, Innovation and Technology (CSIT) is responsible for strengthening the innovation economy within the State, encouraging collaboration and connectivity between industry and academia and the translation of innovations into successful high growth businesses. (www.njeda.gov/csit/)

July 2022

CSR Pharma Group (ChemSun Research) executes Exclusive Global Licensing Agreement for Harvard University Discovery Technology involving a New Cancer Epitope in the Advanced and Metastatic Disease Space.

December 2021